Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

BACKGROUND: As long-term treatment with antitumour necrosis factor (TNF) drugs becomes accepted practice, the risk assessment requires an understanding of anti-TNF long-term safety. Registry safety data in rheumatoid arthritis (RA) are available, but these patients may not be monitored as closely as...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Panaccione, Remo, Gordon, Kenneth B, McIlraith, Melissa J, Lacerda, Ana P M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2013
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595151/
https://www.ncbi.nlm.nih.gov/pubmed/22562972
http://dx.doi.org/10.1136/annrheumdis-2011-201244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595151/
https://www.ncbi.nlm.nih.gov/pubmed/22562972
http://dx.doi.org/10.1136/annrheumdis-2011-201244

Ejemplares similares